Pressemeddelelse

Alligator Bioscience Granted New Composition of Matter Patent in Europe for Mitazalimab

New patent expands protection for mitazalimab in Europe
Patent protects composition of matter for mitazalimab until 2038 (including potential supplementary term)
Mitazalimab IP portfolio now includes 48 granted patents across multiple territories

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Patent Office (EPO) has granted the company a new patent based on EP Patent No. 3323834 covering its lead drug candidate mitazalimab, a CD40 monoclonal antibody currently being evaluated in a Phase 2 study in 1st line metastatic pancreatic cancer.

The patent, titled "Anti-CD40 Antibodies, Uses and Methods", protects composition of matter for mitazalimab and other CD40 monoclonal antibodies until 2038 (including potential supplementary term). The new patent expands protection for mitazalimab in Europe and brings the total number of patents in the mitazalimab intellectual property portfolio to 48 granted patents and 25 pending patents covering multiple territories, including Europe, North America, Asia, and more.

"The protection of our intellectual property is one of the key pillars of our business strategy, providing a strong foundation for our drug development program and our plans to commercialize our assets," said Søren Bregenholt, CEO of Alligator Bioscience. "The granting of this new patent is a significant addition to our overall patent portfolio, providing vital further protection for our lead clinical asset in Europe. It also comes at an excellent timing with mitazalimab making outstanding progress in the clinic and advancing on its route to market."

Mitazalimab is being evaluated in combination with chemotherapy, mFOLFIRINOX, in the OPTIMIZE-1 Phase 2 study in 1st line metastatic pancreatic cancer. The study is progressing and is on track for top-line readout in early Q1 2024.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.